Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

National Institute of Environmental Health Sciences

Use this QR code to view the newest version of this document
Use this QR code to view the newest version of this document

Your Environment. Your Health.

Publication Detail

Title: Pravastatin for Primary Prevention in Older Adults: Restricted Mean Survival Time Analysis.

Authors: Orkaby, Ariela R; Rich, Michael W; Sun, Ryan; Lux, Eliah; Wei, Lee-Jen; Kim, Dae Hyun

Published In J Am Geriatr Soc, (2018 10)

Abstract: To use restricted mean survival time, which summarizes treatment effects in terms of event-free time over a fixed time period, to evaluate the benefit of pravastatin therapy for primary prevention of cardiovascular disease in older adults.Secondary analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial-Lipid-Lowering Trial (ALLHAT-LLT).Ambulatory setting.Individuals aged 65 and older (mean aged 71, 49% female) free of cardiovascular disease (N=2,867).Pravastatin 40 mg/d (n=1,467) versus usual care (n=1,400).We estimated the difference in RMST for total and coronary heart disease (CHD)-free survival between the pravastatin and usual care groups over the 6-year trial period and used parametric survival models to estimate RMST differences projected over 10 years.Over 6 years, individuals treated with pravastatin lived (RMST 2,008.1 days), on average, 33.7 fewer days than those receiving usual care (RMST 2,041.8 days) (difference -33.7 days, 95% confidence interval (CI)=-67.0 to -0.5 days, p=.047). Pravastatin-treated individuals lived RMST 2,088.1 days), on average, 18.7 more days free of CHD over 6 years than those receiving usual care (RMST 2,069.4 days), but this difference was not statistically significant (difference 18.7 days, 95% CI=-10.4-47.8 days, p=.21). The 10-year projection showed that pravastatin-treated individuals would live 108.1 fewer days (95% CI=-204.5 to -14.1, p=.03) than those receiving usual care, although treated individuals would gain 77.9 days (95% CI=3.8-159.6, p=.046) of CHD-free survival.RMST provides an intuitive and explicit way to express the effect of pravastatin therapy on CHD-free and overall survival in older adults free of cardiovascular disease. This measure allows a more personalized interpretation than hazard ratios of the benefits and risks of a medical intervention for decision-making.

PubMed ID: 30251369 Exiting the NIEHS site

MeSH Terms: Aged; Aged, 80 and over; Anticholesteremic Agents/administration & dosage*; Coronary Disease/mortality*; Coronary Disease/prevention & control*; Female; Humans; Male; Middle Aged; Pravastatin/administration & dosage*; Primary Prevention/methods; Primary Prevention/statistics & numerical data*; Proportional Hazards Models; Survival Rate; Time Factors; Treatment Outcome

Back
to Top